Forest plot of HRs for death and 95% CIs for patients treated with FTD/TPI versus placebo, subgrouped according to codonspecific KRAS mutation status. Twosided Wald testbased P values for interaction (as calculated using Cox regression) indicate if the OS benefit of FTD/TPI treatment versus placebo was significantly different between subgroups, for which pairwise comparisons are indicated by the square brackets. a Unadjusted: stratified for two stratification factors of the trial (time from diagnosis of metastases (<18 versus ≥18 months) and region (Japan versus USA, Europe and Australia)). b Adjusted: adjusted by the two stratification factors used in unadjusted analysis plus eight additional baseline characteristics ( Methods ). Note that all Cox regression models passed the proportionalhazards assumption. NE, not estimated; OS, overall survival.
